

Property right statement: Copyright of charts, tables and sentences in this report belongs to ResearchInChina (Beijing Waterwood). For charts or tables marketed as from other sources, original publishers own the copyright. The quoted data in this report are collected from public sources. If there is any problem related to property right, please do not hesitate to contact ResearchInChina.



1. China Vaccine Market in Globalization Process

1.1 Impact of Globalization on China Pharmaceutical Market

Economic globalization is a double-edged sword. On the one hand, economic globalization provides good external environment for China pharmaceutical industry development; it is favorable for Chinese companies to introduce foreign investment, advanced technology & equipment and management experiences and to explore international market; it stimulates Chinese companies to optimize industrial structure, product mix and to improve quality and technology standard. In all, vast opportunities are brought by economic globalization to Chinese enterprises; on the other hand, China pharmaceutical companies have met severe challenges and competition with international giants; in addition to global economic uncertainties, China pharmaceutical companies will face more operation risks.

2.3 Market Structure, 2008

The multinational big companies and China National Biotech Group play the leading role in domestic vaccine market. They have abundant varieties of products and their production lines are much more than other manufacturers. They will continue to maintain the dominance in the next few years.

The second-tier vaccine manufacturers include Liaoning Chengda Biotechnology Co., Ltd. and Shenzhen Kangtai Biological Products Co., Ltd. with over CNY100 million sales. But these companies have few varieties of products.

The third-tier vaccine enterprises are those with less than CNY100 million sales including Zhejiang Pukang Biotechnology Co., Ltd. and Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd. etc.

.



3. Market of Main Varieties of Vaccine, 2008

3.2 China Hepatits B Vaccine Market

3.2.2 Market Size

China has 16 million newborns every year, together with the children in 5 to 12 years old, and the high risk people who engage in special vocation, the demand for preventing hepatitis B gene vaccine is about 32 million people (the equivalent of about 100 million doses). The domestic production could meet the demand, and domestic products account for over 80%. In addition, with the vaccination of healthy adults are carrying out step by step, the hepatitis B vaccine needs are increasing.

3.2.4 Market Price of HB Vaccine

Virus Vaccine - Recombinant (CHO cell) HB Vaccine's

Dosage Form, Price & Origin, 2008

Product	Dosage	Specification	Ceiling Retail	Origin
	Form		Price (Yuan)	
Recombinant (CHO cell) HB	Liquid	10ug×3 /case /person-portion	41.00	Lanzhou
Vaccine				
Recombinant (CHO cell) HB	Liquid	20ug×1/case/person-portion	24.40	Lanzhou
Vaccine				

Source: Medicine Economy Newspaper

Virus Vaccine- Recombinant Yeast HB Vaccine's Dosage Form, Price & Origin, 2008

Product	Dosage Form	Specification	Ceiling Retail Price (Yuan)	Origin
Recombinant	Liquid	5ug×3/case/person		Beijing
(Yeast) HB Vaccine		-portion		
Recombinant	Liquid	10ug×3	48.00	Beijing
(Yeast) HB Vaccine		/case/person-portion		

Source: Medicine Economy Newspaper



5. Import and Export of Vaccine in China

5.1 General Trend of Vaccine Trade

China is the biggest producer and consumer of vaccine. According to statistics from China Customs, Jan to May 2009, total import and export volume of vaccine reached 1,390,613 kg, of which 801,960 kg was the import and 588,653 kg was the export. Jan to May 2009, total import and export value of vaccine amounted to 296,079,218 U.S. dollars, of which \$ 268,637,149 was the import and \$ 27,442,069 was the export.

Jan to Dec 2008, total import and export volume of vaccine was 2,568,970 kg, 1,842,081 of which was the import and 726,889 of which was the export. Jan to Dec 2008, total import and export value of vaccine was 573,210,842 U.S. dollars, of which \$ 526,517,865 was the import and \$ 46,692,977 was the export.

Import and Export of Vaccine in China, 2008

Total Import & Export Value (USD)	573210842	Total Import & Export Volume(kg)	2568970
Import Value	526517865	Import Volume	1842081
Export Value	4669297	Export Volume	726889

Source: China Customs



6. China Key Vaccine Producers

6.1 Main Vaccine Companies

6.1.2 Beijing Tiantan Biological Products Co., Ltd

6.1.2.1Company Profile

Beijing Tiantan Biological Products Co., Ltd specializes in research, production and operation of biological products like vaccine, blood preparations, diagnosis equipment, and now its holding shareholder is China National Biotec Group. With the company development, now it has several holding subsidiaries like Changchun Qifu Biological Products Co., Ltd.

6.1.2.2Operation

Main Businesses of Beijing Tiantan Biological Products Co. by Sector and by Product,
2008

	Business revenue (RMB)	Operation cost (RMB)	Gross Profit Margin (%)	Business revenue y-o-y change (%)	Operation cost y-o-y change (%)	Gross Profit Margin y-o-y change (%)
Prevention	602,432,813.	180,272,356.8	70.08	38.88	41.41	0.53
products	99	1				percentage
						points drop
Blood	70,279,026.3	54,192,400.22	22.89	-22.68	-19.93	2.65
products	9					percentage
						points drop

Source: Beijing Tiantan Biological Products Co., Ltd



Main Businesses of Beijing Tiantan Biological Products Co. by Region, 2008

Area		Business (RMB)	revenue	Y-o-y Change (%)
North China, Northeast	and	249,091,778.27		2.90
Northwest				
South China and East China		245,646,746.90		89.30
Southwest and Middle China		177,973,315.21		16.44
Total		672,711,840.38		28.21

Source: Beijing Tiantan Biological Products Co., Ltd



→ Related Reports

- China Chemical Pharmaceutical Market Report, 2008
 http://www.researchinchina.com/htmls/Report/2008/5622.html
- China Pharmaceutical Chain Industry Report, 2007-2008 http://www.researchinchina.com/htmls/Report/2008/5447.html
- Global and China Medical Devices Industry Report, 2009
 http://www.researchinchina.com/htmls/Report/2009/5723.html
- China Diagnostic Reagent Market Report, 2007-2009
 http://www.researchinchina.com/htmls/Report/2009/5674.html
- China Blood Products Industry Report, 2007-2008
 http://www.researchinchina.com/htmls/Report/2008/5609.html
- China Animal Vaccine Industry Report, 2006-2009
 http://www.researchinchina.com/htmls/Report/2008/5306.html
- China Listed Bio-pharmaceutical Companies Report, 2008
 http://www.researchinchina.com/htmls/Report/2009/5709.html
- Global and China Medical Devices Industry Report, 2009
 <u>http://www.researchinchina.com/htmls/Report/2009/5723.html</u>

China Vaccine Industry Report, 2008-2009

Recearch nChina

About ResearchInChina

ResearchInChina (www.researchinchina.com) is a leading independent provider of China business

intelligence. Our research is designed to meet the diverse planning and information needs of businesses,

institutions, and professional investors worldwide. Our services are used in a variety of ways, including

strategic planning, product and sales forecasting, risk and sensitivity management, and as investment

research.

We have over 500 clients worldwide, including the largest commercial and investment banks; insurance

companies; research institutions; financial services firms; mutual funds; manufacturers; utilities; and

industrial and technology clients.

About InvestToChina

As a connection between global investors and China's fast-growing enterprises, InvestToChina.com

provides the latest and overall market news about China, as well as a full range of professional services,

including Research, Consulting, Due Diligence, and other investment services.

InvestToChina.com offers subscription products for investors, including the China Investment Press,

Market Weekly, Market Monthly and Market Quarterly on various industries. China Investment Press

describes timely investment trends in China. Market Weekly (Monthly and Quarterly) is the important step

to understand the investment potential in China market.

Address: 1102-1105, Tower B, Cai zhi International

Building, Zhongguancun East Road No.18, Haidian

District, Beijing, Post:100083

Tel: 0086-10-82600828, 82600893

Fax: 0086-10-82600829

8